0001127602-23-006586.txt : 20230222 0001127602-23-006586.hdr.sgml : 20230222 20230222205740 ACCESSION NUMBER: 0001127602-23-006586 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230217 FILED AS OF DATE: 20230222 DATE AS OF CHANGE: 20230222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hopper Jonathan Mark CENTRAL INDEX KEY: 0001626325 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 23655639 MAIL ADDRESS: STREET 1: 64 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2023-02-17 0000887359 Vericel Corp VCEL 0001626325 Hopper Jonathan Mark C/O VERICEL CORPORATION 64 SIDNEY STREET CAMBRIDGE MA 02139 1 Chief Medical Officer Common Stock 2023-02-18 4 M 0 2325 0 A 52522 D Common Stock 2023-02-18 4 F 0 1108 29.82 D 51414 D Common Stock 2023-02-19 4 M 0 1750 0 A 53164 D Common Stock 2023-02-19 4 F 0 752 29.82 D 52412 D Stock Option (Right to Buy) 29.82 2023-02-17 4 A 0 1875 0 A 2033-02-17 Common Stock 1875 1875 D Stock Option (Right to Buy) 29.82 2023-02-17 4 A 0 28125 0 A 2033-02-17 Common Stock 28125 28125 D Restricted Stock Unit 2023-02-17 4 A 0 12000 0 A Common Stock 12000 12000 D Restricted Stock Unit 2023-02-18 4 M 0 2325 D Common Stock 2325 6975 D Restricted Stock Unit 2023-02-19 4 M 0 1750 D Common Stock 1750 3500 D The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026. These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024 and February 19, 2025. These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively. No expiration date for this type of award. The Fair Market Value of the vested derivative securities is $29.82 per share. /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper 2023-02-22